Survival Correlates With Adjuvant Choice in Sentinel Node Positive Head and Neck Cutaneous Melanoma
The Laryngoscope · 2025
DOI: 10.1002/lary.32269 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Sina Dadafarin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Head and Neck Neoplasms, Sentinel Lymph Node Biopsy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS, National Institute on Deafness and Other Communication Disorders.
Abstract (Originalsprache)
Objective(s) The objective of this study is to evaluate the utilization and outcomes of completion lymph node dissection (CLND) and immunotherapy for sentinel lymph node biopsy (SLNB) positive head and neck cutaneous melanoma (HNCM).
Methods
Patients with primary HNCM and positive SLNB in the 2020 National Cancer Database (NCDB) Melanoma file were reviewed. The frequency of CLND and immunotherapy was tracked from 2012 to 2019. Clinicodemographic features of patients were evaluated with respect to their post‐SLNB treatment choice. Overall survival (OS) was calculated from the time of diagnosis, and the association of therapy choice with survival was determined using a multivariate Cox regression analysis.
Results
The rates of CLND declined from 66% to 18% while adjuvant immunotherapy increased to a peak of approximately 40%, with an inflection point occurring in 2016. Multivariate survival analysis indicated that immunotherapy use alone, though not CLND, was associated with improved prognosis (hazard ratio 0.65, 95% confidence interval 0.45–0.93). Patient characteristics associated with immunotherapy administration included age ( p < 0.01), insurance type ( p = 0.002), income ( p < 0.001), and healthcare facility type ( p = 0.005).
Conclusion
In this retrospective NCDB‐based study, we find that the modern management of SLNB‐positive patients has shifted towards greater use of adjuvant immunotherapy and a decline in CLND; the use of immunotherapy is associated with improved OS. Patients treated with immunotherapy were more likely to be younger, of higher income, and with private health insurance. Level of Evidence 4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington, USA.
- Division of Neurosurgery & Spine Program, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
- Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
- Department of Otolaryngology - Head and Neck Surgery, Saint Louis University School of Medicine, St. Louis, Missouri, USA.
- Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Hematology and Oncology, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Sina Dadafarin, Sean T Massa, Zain H Rizvi
Förderung
- NIDCD NIH HHS
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Dadafarin, S., Alvi, M. A., Massa, S. T., Veatch, J., & Rizvi, Z. H. (2025). Survival Correlates With Adjuvant Choice in Sentinel Node Positive Head and Neck Cutaneous Melanoma. The Laryngoscope. https://doi.org/10.1002/lary.32269
Vancouver
Dadafarin S, Alvi MA, Massa ST, Veatch J, Rizvi ZH. Survival Correlates With Adjuvant Choice in Sentinel Node Positive Head and Neck Cutaneous Melanoma. The Laryngoscope. 2025. doi:10.1002/lary.32269
BibTeX
@article{Dadafarin2025,
author = {Dadafarin, Sina and Alvi, Mohammed A and Massa, Sean T and Veatch, Joshua and Rizvi, Zain H},
title = {Survival Correlates With Adjuvant Choice in Sentinel Node Positive Head and Neck Cutaneous Melanoma},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.32269}
}
EUVIMED